Chemed (CHE) EBITDA (2009 - 2026)

Chemed has reported EBITDA for 18 years, with the latest figure at $98.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 8.62% year-over-year to $98.9 million; the trailing twelve-month figure through Mar 2026 stood at $383.5 million (down 13.23% YoY), and the FY2025 full-year result was $392.8 million, down 6.33% from the prior year.
• EBITDA for Q1 2026 stood at $98.9 million, down from $114.4 million in the prior quarter.
• The five-year high for EBITDA was $127.1 million in Q4 2024, with the low at -$180.8 million in Q4 2022.
• Average EBITDA over 5 years is $83.6 million, with a median of $99.7 million recorded in 2023.
• Peak annual rise in EBITDA reached 168.8% in 2023, while the deepest fall reached 21.51% in 2023.
• Tracing CHE's EBITDA over 5 years: stood at -$180.8 million in 2022, then surged by 168.8% to $124.4 million in 2023, then increased by 2.19% to $127.1 million in 2024, then retreated by 10.01% to $114.4 million in 2025, then decreased by 13.58% to $98.9 million in 2026.
• The last three EBITDA figures came in at $98.9 million (Q1 2026), $114.4 million (Q4 2025), and $88.4 million (Q3 2025), per Business Quant data.

Peer Comparison